News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,640 Results
Type
Article (41821)
Company Profile (473)
Press Release (661346)
Section
Business (208468)
Career Advice (2011)
Deals (35955)
Drug Delivery (100)
Drug Development (83467)
Employer Resources (169)
FDA (16352)
Job Trends (15056)
News (352305)
Policy (33042)
Tag
Academia (2624)
Alliances (50709)
Alzheimer's disease (1302)
Approvals (16292)
Artificial intelligence (155)
Bankruptcy (361)
Best Places to Work (11787)
Biotechnology (355)
Breast cancer (193)
Cancer (1406)
Cardiovascular disease (117)
Career advice (1678)
Cell therapy (301)
Clinical research (66489)
Collaboration (509)
Compensation (263)
COVID-19 (2676)
C-suite (114)
Data (1413)
Diabetes (176)
Diagnostics (6231)
Earnings (86128)
Employer resources (147)
Events (113491)
Executive appointments (402)
FDA (17037)
Funding (447)
Gene therapy (213)
GLP-1 (634)
Government (4445)
Healthcare (19033)
Infectious disease (2770)
Inflammatory bowel disease (118)
Interviews (309)
IPO (16619)
Job creations (3697)
Job search strategy (1431)
Layoffs (445)
Legal (7943)
Lung cancer (202)
Lymphoma (100)
Manufacturing (217)
Medical device (13359)
Medtech (13364)
Mergers & acquisitions (19488)
Metabolic disorders (479)
Neuroscience (1642)
NextGen Class of 2024 (6739)
Non-profit (4537)
Northern California (1716)
Obesity (273)
Opinion (202)
Patents (119)
People (57829)
Phase I (20861)
Phase II (29350)
Phase III (21709)
Pipeline (525)
Postmarket research (2599)
Preclinical (8940)
Radiopharmaceuticals (252)
Rare diseases (278)
Real estate (5999)
Regulatory (22126)
Research institute (2407)
Resumes & cover letters (351)
Southern California (1490)
Startups (3747)
United States (15607)
Vaccines (611)
Weight loss (199)
Date
Last 7 days (601)
Last 30 days (2398)
Last 365 days (36272)
2024 (36106)
2023 (41024)
2022 (52296)
2021 (56803)
2020 (54958)
2019 (47420)
2018 (35699)
2017 (33027)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (733)
Arizona (203)
Asia (38673)
Australia (6434)
California (3917)
Canada (1458)
China (310)
Colorado (175)
Connecticut (187)
Europe (84357)
Florida (537)
Georgia (135)
Illinois (398)
Indiana (227)
Maryland (642)
Massachusetts (3095)
Michigan (174)
Minnesota (296)
New Jersey (1124)
New York (1099)
North Carolina (802)
Northern California (1716)
Ohio (148)
Pennsylvania (934)
South America (1106)
Southern California (1490)
Texas (563)
Utah (110)
Washington State (413)
703,640 Results for "moderna therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RSV
FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues
Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, FDA advisors said the trial investigators should continue the study, while keeping an eye out for further safety signals.
December 13, 2024
·
3 min read
·
Tristan Manalac
Job Creations
Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs
Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in Massachusetts. Moderna and Vertex received the largest awards and will add over 600 combined jobs.
October 24, 2024
·
4 min read
·
Angela Gabriel
Earnings
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
November 7, 2024
·
3 min read
·
Tristan Manalac
Patents
GSK Sues Moderna for Alleged Patent Infringement on COVID-19, RSV Vaccines
The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and respiratory syncytial virus shot mResvia.
October 16, 2024
·
2 min read
·
Tristan Manalac
Press Releases
BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
December 5, 2024
·
6 min read
Business
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate (“Development Candidate”), under its collaboration with Moderna, Inc.
June 27, 2024
·
6 min read
Drug Development
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028
Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in preparation for the launch of up to 10 new products.
September 13, 2024
·
4 min read
·
Annalee Armstrong
Podcast
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals through 2027; more oral obesity drug data; the latest from ESMO and more.
September 18, 2024
·
1 min read
·
Heather McKenzie
Genetown
Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.
June 6, 2024
·
5 min read
News
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
September 30, 2024
·
4 min read
1 of 70,364
Next
